Parkinson’s Foundation Highlights Study on CND Life Sciences’ Syn-One Test® in Top 2024 Science News Articles
The Parkinson’s Foundation published its Top Parkinson’s Science News Articles of 2024, featuring a study on the Syn-One Test® from CND Life Sciences first on the list
Diagnosing Parkinson’s disease (PD) can be challenging due to the absence of a single definitive test, often resulting in delayed diagnosis. A study in the Journal of the American Medical Association (JAMA) revealed that a skin biopsy test can reliably detect the protein indicative of PD and related diseases, known as synucleinopathies, which include dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF). These diseases are characterized by the accumulation of phosphorylated (abnormal) alpha-synuclein (P-SYN) in nerve cells.
The study found that analyzing small skin biopsies from the leg, thigh, and back of the neck with the Syn-One Test® can detect P-SYN in individuals with synucleinopathies. In a group of 428 participants, the test showed a 92.7% positive rate for Parkinson’s, 98.2% for MSA, 96% for DLB, and 100% for PAF. Only 3.3% of biopsies from participants without neurodegenerative disease tested positive for P-SYN, indicating a 96.7% specificity in the study.
Researchers also discovered a correlation between the amount of P-SYN and the severity of symptoms, suggesting the potential of the test to not only aid in diagnosis but also monitor disease progression. The skin biopsy method offers practical and reliable method for supporting clinicians in diagnosing patients.
